» Articles » PMID: 23795223

A Novel Approach to Improve Health Status Measurement in Observational Claims-based Studies of Cancer Treatment and Outcomes

Overview
Journal J Geriatr Oncol
Publisher Elsevier
Specialty Geriatrics
Date 2013 Jun 25
PMID 23795223
Citations 82
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: To develop and provide initial validation for amultivariate, claims-based prediction model for disability status (DS), a proxymeasure of performance status (PS), among older adults. The model was designed to augment information on health status at the point of cancer diagnosis in studies using insurance claims to examine cancer treatment and outcomes.

Materials And Methods: We used data from the 2001–2005 Medicare Current Beneficiary Survey (MCBS), with observations randomly split into estimation and validation subsamples. We developed an algorithm linking self-reported functional status measures to a DS scale, a proxy for the Eastern Cooperative Oncology Group (ECOG) PS scale. The DS measure was dichotomized to focus on good [ECOG 0–2] versus poor [ECOG 3–4] PS. We identified potential claims-based predictors, and estimated multivariate logistic regression models, with poor DS as the dependent measure, using a stepwise approach to select the optimal model. Construct validity was tested by determining whether the predicted DS measure generated by the model was a significant predictor of survival within a validation sample from the MCBS.

Results And Conclusion: One-tenth of the beneficiaries met the definition for poor DS. The base model yielded high sensitivity (0.79) and specificity (0.92); positive predictive value=48.3% and negative predictive value=97.8%, c-statistic=0.92 and good model calibration. Adjusted poor claims-based DS was associated with an increased hazard of death (HR=3.53, 95% CI 3.18, 3.92). The ability to assess DS should improve covariate control and reduce indication bias in observational studies of cancer treatment and outcomes based on insurance claims.

Citing Articles

The association between toxicity and efficacy of immune checkpoint inhibitors in older adults with NSCLC.

Rong Y, Ramachandran S, Bhattacharya K, Yang Y, Earl S, Chang Y Immunotherapy. 2024; 16(16-17):1057-1068.

PMID: 39268919 PMC: 11492704. DOI: 10.1080/1750743X.2024.2394382.


Unleashing frailty from laboratory into real world: A critical step toward frailty-guided clinical care of older adults.

Kim D J Am Geriatr Soc. 2024; 72(11):3299-3314.

PMID: 39166879 PMC: 11560722. DOI: 10.1111/jgs.19151.


Immune checkpoint inhibitors as subsequent treatment in older adults with non-small cell lung cancer and synchronous brain metastases.

Mahashabde R, Bhatti S, Martin B, Painter J, Rodriguez A, Ying J Transl Lung Cancer Res. 2024; 13(7):1620-1634.

PMID: 39118898 PMC: 11304147. DOI: 10.21037/tlcr-24-205.


Assessing the Benefits and Harms of Pharmacotherapy in Older Adults with Frailty: Insights from Pharmacoepidemiologic Studies of Routine Health Care Data.

Kim D, Park C, Ko D, Lin K, Glynn R Drugs Aging. 2024; 41(7):583-600.

PMID: 38954400 PMC: 11884328. DOI: 10.1007/s40266-024-01121-0.


Predictors of high-intensity care at the end of life among older adults with solid tumors: A population-based study.

Baird C, Wulff-Burchfield E, Egan P, Hugar L, Vyas A, Trikalinos N J Geriatr Oncol. 2024; 15(5):101774.

PMID: 38676975 PMC: 11162260. DOI: 10.1016/j.jgo.2024.101774.


References
1.
Fleurence R, Naci H, Jansen J . The critical role of observational evidence in comparative effectiveness research. Health Aff (Millwood). 2010; 29(10):1826-33. DOI: 10.1377/hlthaff.2010.0630. View

2.
Oken M, Creech R, Tormey D, Horton J, Davis T, McFadden E . Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982; 5(6):649-55. View

3.
Potosky A, Riley G, Lubitz J, Mentnech R, Kessler L . Potential for cancer related health services research using a linked Medicare-tumor registry database. Med Care. 1993; 31(8):732-48. View

4.
Warren J, Klabunde C, Schrag D, Bach P, Riley G . Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med Care. 2002; 40(8 Suppl):IV-3-18. DOI: 10.1097/01.MLR.0000020942.47004.03. View

5.
Davidoff A, Gardner J, Seal B, Edelman M . Population-based estimates of survival benefit associated with combined modality therapy in elderly patients with locally advanced non-small cell lung cancer. J Thorac Oncol. 2011; 6(5):934-41. DOI: 10.1097/JTO.0b013e31820eed00. View